期刊文献+

高强度聚焦超声治疗前列腺癌的研究现状 被引量:3

The current investigation status of high intensity focused ultrasound treating prostate cancer
原文传递
导出
摘要 作为常见肿瘤的前列腺癌,其发病率逐年上升。手术是局限性病变的主要治疗手段,但仍然有一定的并发症和死亡率。放化疗等传统治疗手段也有其适应证和疗效的局限性,迫切需要有效的微创治疗方法。近年发展起来的高强度聚焦超声(HIFU)正日益受到人们的关注,对其作用机制、设备原理、适应证、治疗效果和局限性等问题作综述。 Being the common tumor forms,prostate cancer, its incidence is ascending year after year. Although surgery is the key treatment means in local prostate cancer, but the complications and mortality rate are frequently observed. Radiotherapy and chemotherapy, the traditional measures in prostate cancer treatment,are limited by the indication and relatively lower curative effect. So, needs to look for effective microinvasion treatments. As the new technique of microinvasion, high intensity focused ultrasound-HIFU, is remarkerablely noticed by people, in this paper, the mechanism ;equipment, clinical effect and limitation were summarized.
出处 《肿瘤研究与临床》 CAS 2006年第11期782-784,共3页 Cancer Research and Clinic
关键词 高强度聚焦超声治疗 前列腺癌 High intensity focused ultrasound treating Prostate cancer
  • 相关文献

参考文献29

  • 1Jemal A,Siegel R,Ward E,et al.Cancer statistics,2006[J].CA Cancer J Clin,2006,56(2):106-130.
  • 2Walsh P C,Partin A W,Epstein J I.Cancer control and quality of life following anatomical radical retropubic prostatectomy:results at 10 years[J].J Urol,1994,152(5 Pt 2):1831-1836.
  • 3Augustin H,Hammerer P,Graefen M,et al.Intraoperative and perioperative morbidity of contemporary radical retropubic prostatectomy in a consecutive series of 1243 patients:results of a single center between 1999 and 2002[J].Eur Urol,2003,43(2):113-118.
  • 4Benoit R M,Naslund M J,Cohen J K.Complications after radical retropubic prostatectomy in the medicare population[J].Urology,2000,56(1):116-120.
  • 5Ahmed S,Lindsey B,Davies J.Emerging minimally invasive techniques for treating localized prostate cancer[J].BJU Int,2005,96(9):1230-1234.
  • 6Lerner S E,Blute M L,Zinke H.Critical evaluation of salvage surgery for radio-recurrent/resistant prostate cancer[J].J Urol,1995,154(3):1103-1109.
  • 7Bihrler R,Foster R S,Shanghvi N T,et al.High intensity focused ultrasound for the treatment of benign prostatic hyperplasia early United States clinical experience[J].J Urol,1994,151(5):1271-1275.
  • 8Colombel M,Gelet A.Principles and results of high-intensity focused ultrasound for localized prostate cancer[J].Prostate Cancer Prostatic Dis,2004,7(4):289-294.
  • 9刘丽霞,叶欣.高强度聚焦超声治疗与肿瘤免疫[J].肿瘤研究与临床,2005,17(2):140-141. 被引量:11
  • 10叶欣,费兴波,何申戌.高强度聚焦超声治疗肿瘤[J].国外医学(肿瘤学分册),2004,31(1):38-40. 被引量:71

二级参考文献74

  • 1叶欣 ,费兴波 ,赫崇军 ,李毅 ,候刚 ,葛忠民 ,赵正军 ,张军 .老年转移性肝癌患者高强度聚焦超声热疗后Th1/Th2漂移的研究[J].中华医学超声杂志(电子版),2004,1(2):76-76. 被引量:20
  • 2叶欣,葛忠民,吴珂,侯刚,赵正军.高强度聚焦超声治疗脾功能亢进的初步研究[J].医学研究通讯,2004,33(7):59-60. 被引量:5
  • 3叶欣,费兴波,赫崇军,侯刚,李毅,葛忠民,赵正军,张军.高强度聚焦超声治疗肝癌后免疫功能的变化[J].中国肿瘤临床与康复,2005,12(1):23-25. 被引量:20
  • 4刘耀庭,程伟,李秀霞.泌尿外科肿瘤发病情况的变化[J].临床泌尿外科杂志,1997,12(1):47-48. 被引量:39
  • 5申文江.前列腺癌的放疗[A].见:主编:郭应禄.前列腺增生及前列腺癌[C].北京:人民卫生出版社,1998.226.
  • 6Chen I, Rivens I, Ter Haar GR, et al. Histological changes in rat liver tumours treated with high-intensity focused ultrasound. Ultrasound in Med Biol 1993;19:67 - 74.
  • 7Strauss SA, Appel M, Saphir O, et al. Immunologic resistance to carcinoma produced by electrocoagulation. Surg Cynecol Obstet 1965 ; 121 (5) : 989 - 96.
  • 8Rowland IJ, Rivens I, Chen L, et al. MRI study of hepatic tumours following high intensity focused ultrasound surgery[J]. Br J Radiol, 1997,70:144-153.
  • 9Yang R, Reilly C R, Rescorla F J, et al. Effects of high intensity focused ultrasound in the treatment of experimental neuroblastoma[J]. Pediatr Surg, 1992, 27(2):246-251.
  • 10Szmigielski S, Sobczynski J, Sokolska G, et al. Effects of local prostatic hyperthermia on human NK and T cell function [J]. Int J Hyperthermia, 1991, 7(6):869-880.

共引文献108

同被引文献78

  • 1易静,郝晓柯,苏明权.前列腺癌的基因治疗研究进展[J].肿瘤研究与临床,2004,16(6):428-430. 被引量:3
  • 2Lassi K, Dawson NA. Update on castrate-resistant prostate cancer. Curr Opin Oncol, 2010, 22:263-267.
  • 3de Bono JS, Oudard S, Ozguroglu M, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing afler docetaxel treatment: a randomised open-label trial. Lancet, 2010,376:1147-1154.
  • 4Villanueva C, Bazan F. Kim S, et al. Cabazitaxel: a novel microtubule inhibitor. Drugs, 2011, 71:1251-1258.
  • 5Rosenberg JE, Weinberg VK, Kelly WK, et al. Activity of second-line chemotherapy in docetaxel-refractory hormone-refractory prostate cancer patients: randomized phase 2 study of ixabepilone or mitoxantrone and prednisone. Cancer, 2007, 110:556-563.
  • 6Hussain M, Tangen CM, Lara PN, et al. Ixabepilone (epothilone B analogue BMS-247550) is active in chemotherapy-naive patients with hormonerefractory prostate cancer: a Southwest Oncology Group trial S0111. J Clin Oncol, 2005, 23:8724-8729.
  • 7Chi KN, Beardsley E, Eigl BJ, et al. A phase 2 study of patupilone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxeh Canadian Urologic Oncology Group study P07a. Ann Oncol, 2012, 23:53-58.
  • 8Locke JA, Guns ES, Lubik AA, et al. Androgen levels increase by intratumoral de novo steroidogenesis during progression of castration- resistant prostate cancer. Cancer Res, 2008, 68:6407-6415.
  • 9Montgomery RB, Mostaghel EA, Vessella R, et al. Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. Cancer Res, 2008, 68:4447-4454.
  • 10Yap TA, Carden CP, Attard G, et al. Targeting GYP17:established and novel approaches in prostate cancer. Curr Opin Pharmacol, 2008, 8: 449-457.

引证文献3

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部